Hepatology research : the official journal of the Japan Society of Hepatology · 2026
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moriyama Etsuko, Koga Hironori, Niizeki Takashi, Iwamoto Hideki, Shimose Shigeo, Shirono Tomotake, Tokushige Takahiko, Nakano Masahito, Kuromatsu Ryoko, Goto Toru, Honda Masaki, Hibi Taizo, Mikami Yoshiki, Kondo Reiichiro, Akiba Jun, Kawaguchi Takumi
Аннотация
BACKGROUND: Malignant hepatocellular neoplasm, not otherwise specified (HCN, NOS), is a rare primary liver tumor showing overlapping features of hepatoblastoma and hepatocellular carcinoma. Because of its rarity and histopathologic heterogeneity, the optimal treatment strategy for HCN, NOS remains undefined.
AIM AND METHODS: We report a case of a 20-year-old woman with initially unresectable HCN, NOS, who was treated with hepatic arterial infusion chemotherapy using a fine-powder formulation of cisplatin suspended in Lipiodol combined with continuous 5-fluorouracil administration (New FP). The therapeutic response was assessed radiologically and serologically after each treatment cycle, and the patient subsequently underwent surgical resection after adequate tumor regression.
RESULTS: After eight cycles of New FP, marked tumor shrinkage and a significant decline in tumor markers were achieved, enabling subsequent systemic chemotherapy according to the SIOPEL-4 regimen. Thereafter, conversion hepatectomy was performed, and histological examination of the resected specimen demonstrated approximately 90% tumor necrosis. The patient has remained disease-free for 20 months after surgery.
CONCLUSION: This case demonstrates the potential of New FP as an effective hepatic arterial infusion regimen capable of achieving conversion therapy in rare liver malignancies such as HCN, NOS.
AIM AND METHODS: We report a case of a 20-year-old woman with initially unresectable HCN, NOS, who was treated with hepatic arterial infusion chemotherapy using a fine-powder formulation of cisplatin suspended in Lipiodol combined with continuous 5-fluorouracil administration (New FP). The therapeutic response was assessed radiologically and serologically after each treatment cycle, and the patient subsequently underwent surgical resection after adequate tumor regression.
RESULTS: After eight cycles of New FP, marked tumor shrinkage and a significant decline in tumor markers were achieved, enabling subsequent systemic chemotherapy according to the SIOPEL-4 regimen. Thereafter, conversion hepatectomy was performed, and histological examination of the resected specimen demonstrated approximately 90% tumor necrosis. The patient has remained disease-free for 20 months after surgery.
CONCLUSION: This case demonstrates the potential of New FP as an effective hepatic arterial infusion regimen capable of achieving conversion therapy in rare liver malignancies such as HCN, NOS.